Last reviewed · How we verify
KSD-101
At a glance
| Generic name | KSD-101 |
|---|---|
| Sponsor | Kousai Bio Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (EARLY_PHASE1)
- KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (EARLY_PHASE1)
- KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial (EARLY_PHASE1)
- KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (EARLY_PHASE1)
- KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KSD-101 CI brief — competitive landscape report
- KSD-101 updates RSS · CI watch RSS
- Kousai Bio Co., Ltd. portfolio CI